August 2019

No Image

Canopy Rivers Announces Health Canada Approval for Significant Expansion to the Licensed Infrastructure at Radicle

TORONTO, Aug. 1, 2019 /PRNewswire/ – Canopy Rivers Inc. (“Canopy Rivers” or the “Company”) (TSXV: RIV) (OTC: CNPOF) is pleased to announce that its portfolio company Radicle Medical Marijuana Inc. (“Radicle”) has received approval from Health Canada for its production facility expansion project. This approval effectively doubles Radicle’s production footprint, significantly increasing its capacity to 6,000 kilograms per year.

No Image

Medical Marijuana, Inc. Subsidiary Kannaway® Enters Strategic Partnership With Endocanna Health to Create and Sell Endocannabinoid DNA Test Products

SAN DIEGO, Aug. 1, 2019 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first publicly traded cannabis company in the United States that launched the world’s preeminent cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has entered a strategic partnership with Endocanna Health, Inc., (“Endocanna”) a research and development biotechnology company specializing in endocannabinioid DNA testing and personalization.

No Image

Khiron Begins Pre-clinical Medical Cannabis Studies with Leading Academic Institutes in Uruguay

TORONTO, Aug. 1, 2019 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that it has initiated pre-clinical medical cannabis studies with the Universidad de la República of Uruguay and Institut Pasteur de Montevideo. These studies, which have been approved by the IRCCA (Instituto de Regulación y Control del Cannabis – the Regulatory Cannabis State Authority of Uruguay), will focus on the effects of three licensed Khiron strains targeting inflammation, oxidative and nervous system disorders, and mark an important development phase as the Company moves towards medical registration and sale of its products in Latin America and for export worldwide.